Neurocrine Tardive Dyskinesia Drug Hits, Stock Jumps
Biotech Neurocrine Biosciences (NBIX) said Thursday that its drug for tardive dyskinesia had succeeded in a late-stage trial, sending its stock up sharply in early trading. Tardive dyskinesia is a syndrome that causes involuntary, repetitive movements, generally as a side effect of antipsychotic drugs. So the patients in Neurocrine’s trial, called Kinect 3, had severe psychiatric disorders along with their TD. Neurocrine said that patients who